Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.71 (1y: -75%)
Market Cap 74.34 M P/E(ttm)
Enterprise Value P/B 1.00
ENZN- NAS (USA)
Enzon Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$1.71
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 1.698
ENZN's Cash to Debt is ranked higher than
65% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ENZN: 1.698 )
ENZN' s 10-Year Cash to Debt Range
Min: 0.23   Max: No Debt
Current: 1.7
Equity to Asset 0.388
ENZN's Equity to Asset is ranked higher than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ENZN: 0.388 )
ENZN' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.93
Current: 0.39
-0.14
0.93
F-Score: 6
Z-Score: -0.06
M-Score: -5.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -9.30
ENZN's Operating margin (%) is ranked higher than
65% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ENZN: -9.30 )
ENZN' s 10-Year Operating margin (%) Range
Min: -54.1   Max: 48.8
Current: -9.3
-54.1
48.8
Net-margin (%) -6.5
ENZN's Net-margin (%) is ranked higher than
66% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ENZN: -6.5 )
ENZN' s 10-Year Net-margin (%) Range
Min: -53.9   Max: 181.1
Current: -6.5
-53.9
181.1
ROE (%) -3.6
ENZN's ROE (%) is ranked higher than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZN: -3.6 )
ENZN' s 10-Year ROE (%) Range
Min: -44   Max: 227.1
Current: -3.6
-44
227.1
ROA (%) -1.4
ENZN's ROA (%) is ranked higher than
66% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ENZN: -1.4 )
ENZN' s 10-Year ROA (%) Range
Min: -14   Max: 36.3
Current: -1.4
-14
36.3
Revenue Growth (%) -31.1
ENZN's Revenue Growth (%) is ranked lower than
57% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZN: -31.1 )
ENZN' s 10-Year Revenue Growth (%) Range
Min: -32.3   Max: 65.3
Current: -31.1
-32.3
65.3
EBITDA Growth (%) -60.9
ENZN's EBITDA Growth (%) is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZN: -60.9 )
ENZN' s 10-Year EBITDA Growth (%) Range
Min: -60.9   Max: 79.7
Current: -60.9
-60.9
79.7
» ENZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ENZN Guru Trades in Q2 2012

First Pacific Advisors 379,826 sh (New)
Charles Brandes 51,070 sh (+58.41%)
Carl Icahn 5,904,863 sh (unchged)
Seth Klarman 9,000,878 sh (unchged)
Michael Price 755,000 sh (unchged)
Jean-Marie Eveillard 1,124,580 sh (-4.88%)
Jim Simons 1,269,384 sh (-12.15%)
Jeremy Grantham 99,400 sh (-52.98%)
» More
Q3 2012

ENZN Guru Trades in Q3 2012

Seth Klarman 9,000,878 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 379,826 sh (unchged)
Michael Price 755,000 sh (unchged)
Charles Brandes 50,160 sh (-1.78%)
Jim Simons 1,143,184 sh (-9.94%)
Jean-Marie Eveillard 490,142 sh (-56.42%)
Jeremy Grantham 35,000 sh (-64.79%)
» More
Q4 2012

ENZN Guru Trades in Q4 2012

Charles Brandes 67,810 sh (+35.19%)
First Pacific Advisors 379,826 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Jean-Marie Eveillard Sold Out
Michael Price 748,800 sh (-0.82%)
Seth Klarman 7,850,368 sh (-12.78%)
Jim Simons 980,984 sh (-14.19%)
» More
Q1 2013

ENZN Guru Trades in Q1 2013

Charles Brandes 360,865 sh (+432.17%)
Michael Price 748,800 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 379,826 sh (unchged)
Seth Klarman 7,691,453 sh (-2.02%)
Jim Simons 886,184 sh (-9.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2013-03-31 Add 432.17%0.01%$3.79 - $4.99 $ 1.71-62%360865
Jean-Marie Eveillard 2012-12-31 Sold Out 0.01%$4.35 - $7 $ 1.71-72%0
Charles Brandes 2012-12-31 Add 35.19%$4.35 - $7 $ 1.71-72%67810
Jean-Marie Eveillard 2012-09-30 Reduce -56.42%0.02%$6.42 - $7.17 $ 1.71-75%490142
Charles Brandes 2012-06-30 Add 58.41%$5.87 - $7.06 $ 1.71-73%51070
Charles Brandes 2012-03-31 New Buy$6.54 - $7.82 $ 1.71-74%32240
Richard Perry 2011-09-30 Sold Out 0.5937%$7.24 - $10.37 $ 1.71-81%0
Carl Icahn 2011-09-30 Add 25%0.07%$7.24 - $10.37 $ 1.71-81%5904863
Richard Perry 2011-06-30 Reduce -30.35%0.31%$9.97 - $11.81 $ 1.71-84%2013000
George Soros 2011-06-30 Sold Out $9.97 - $11.81 $ 1.71-84%0
Michael Price 2011-03-31 Add 16.65%0.16%$10.14 - $12.48 $ 1.71-85%700000
George Soros 2011-03-31 Reduce -52.5%$10.14 - $12.48 $ 1.71-85%30400
Carl Icahn 2010-12-31 Add 67.7%0.41%$10.5 - $12.5 $ 1.71-85%4723891
Seth Klarman 2010-09-30 Add 2.03%0.14%$10.25 - $11.28 $ 1.71-84%10382698
George Soros 2010-09-30 Add 481.74%0.01%$10.25 - $11.28 $ 1.71-84%66900
Seth Klarman 2010-06-30 Add 10.57%0.78%$10.07 - $11.45 $ 1.71-84%10175898
Richard Perry 2010-06-30 Add 285.39%0.63%$10.07 - $11.45 $ 1.71-84%2880000
George Soros 2010-06-30 New Buy$10.07 - $11.45 $ 1.71-84%11500
Seth Klarman 2010-03-31 Add 13.87%0.7%$9 - $11.28 $ 1.71-83%9203100
Michael Price 2010-03-31 Add 137.9%0.64%$9 - $11.28 $ 1.71-83%530000
Richard Perry 2010-03-31 New Buy0.22%$9 - $11.28 $ 1.71-83%747300
George Soros 2010-03-31 Sold Out 0.01%$9 - $11.28 $ 1.71-83%0
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 1.00
ENZN's P/B is ranked higher than
94% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. ENZN: 1.00 )
ENZN' s 10-Year P/B Range
Min: 0.9   Max: 36.59
Current: 1
0.9
36.59
P/S 2.00
ENZN's P/S is ranked higher than
89% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ENZN: 2.00 )
ENZN' s 10-Year P/S Range
Min: 0.96   Max: 173.2
Current: 2
0.96
173.2
PFCF 7.60
ENZN's PFCF is ranked higher than
90% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. ENZN: 7.60 )
ENZN' s 10-Year PFCF Range
Min: 4.73   Max: 942.38
Current: 7.6
4.73
942.38
EV-to-EBIT 6.3
ENZN's EV-to-EBIT is ranked higher than
94% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. ENZN: 6.3 )
ENZN' s 10-Year EV-to-EBIT Range
Min: 5   Max: 2000.2
Current: 6.3
5
2000.2
Shiller P/E 3.1
ENZN's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. ENZN: 3.1 )
ENZN' s 10-Year Shiller P/E Range
Min: 2.75   Max: 795.83
Current: 3.1
2.75
795.83

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 1
ENZN's Price/Net Cash is ranked higher than
97% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 8.90 vs. ENZN: 1 )
ENZN' s 10-Year Price/Net Cash Range
Min: 2.6   Max: 93.3
Current: 1
2.6
93.3
Price/Net Current Asset Value 57
ENZN's Price/Net Current Asset Value is ranked higher than
63% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. ENZN: 57 )
ENZN' s 10-Year Price/Net Current Asset Value Range
Min: 13.8   Max: 670
Current: 57
13.8
670
Price/Tangible Book 1
ENZN's Price/Tangible Book is ranked higher than
96% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. ENZN: 1 )
ENZN' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 131.6
Current: 1
1.8
131.6
Price/DCF (Projected) 0.2
ENZN's Price/DCF (Projected) is ranked higher than
99% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ENZN: 0.2 )
ENZN' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 8.3
Current: 0.2
0.7
8.3
Price/Median PS Value 0.5
ENZN's Price/Median PS Value is ranked higher than
91% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ENZN: 0.5 )
ENZN' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 26.2
Current: 0.5
0.4
26.2
Earnings Yield (Greenblatt) 15.80
ENZN's Earnings Yield (Greenblatt) is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZN: 15.80 )
ENZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 19.9
Current: 15.8
0.1
19.9
Forward Rate of Return (Yacktman) 18.44
ENZN's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ENZN: 18.44 )
ENZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.6   Max: 26.9
Current: 18.44
-10.6
26.9

Business Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company is engaged in developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. Its drug development programs utilize two platforms - Customized PEGylation Linker Technology and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. It currently has four compounds in human clinical development - a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists targeting Hypoxia-Inducible Factor-1α (HIF-1α), Survivin and the Androgen Receptor (AR). In addition, it has novel mRNA antagonist targets in various stages of preclinical research. PEGylation has successfully been used on various pharmaceutical compounds (e.g. enzymes, peptides, antibody/antibody fragments and small molecules) to improve their pharmaceutical properties. By attaching polyethylene glycol (PEG) to a pharmaceutical compound using a spectrum of stable or releasable linkers, its Customized Linker Technology has the potential to overcome pharmaceutical limitations for a broad universe of molecules and generate compounds with substantially enhanced therapeutic value over their unmodified forms. The Company is using LNA technology to develop mRNA antagonists against novel oncology targets. LNA technology allows the development of very selective antagonists that act through the antisense RNAase H principle. Drugs based on the antisense principle work by providing a synthetic strand of nucleic acid that bind to the mRNA and degrade it by endogenous RNAase H. Due to the elimination of mRNA, there is no mRNA template to produce a protein. In pre-clinical studies, the LNA technology has been shown to provide mRNA antagonists with significantly enhanced binding affinity to complementary RNA sequences, high potencies, long tissue half-lives, and improved therapeutic ratios over first- and second-generation antisense drugs. The Company competes with biotechnology and specialized biopharmaceutical firms and large pharmaceutical companies with respect to the partnering and licensing of research and the development of product candidates. The Company's operations are also subject to federal, state and local environmental laws and regulations concerning, among other things, the generation, handling, storage, transportation, treatment and disposal of hazardous, toxic and radioactive substances and the discharge of pollutants into the air and water.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:EZ1.Germany
» More Articles for ENZN

Headlines

Articles On GuruFocus.com
First Pacific Advisors’ Top New Buys Aug 08 2012 
Enzon Inc. Reports Operating Results (10-K) Mar 16 2011 
Carl Icahn Buys NAV, CHK, ENZN, AMLN, CMC, Feb 15 2011 
Despite Bearish View, Seth Klarman Holds These Stocks: VSAT, THRX, NWSA, BBEP, ENZN, CSE Nov 25 2010 
Enzon Inc. Reports Operating Results (10-Q) Nov 04 2010 
Stocks Seth Klarman Keeps Buying: VSAT and ENZN; and Selling: NWSA, UFS, VOXX Sep 20 2010 
Hedge Fund Perry Capital Buys Gilead Sciences Inc., CocaCola Enterprises, Questar Corp., Sells Alcon Aug 19 2010 
Seth Klarman Buys Energy XXI, Viasat Inc., Enzon Inc., Sells Directv Group Inc., Domtar Corp Aug 14 2010 
Enzon Inc. Reports Operating Results (10-Q) Aug 09 2010 
Enzon Inc. (ENZN) Exec VP Finance, CFO Craig A Tooman sells 123,100 Shares Jun 22 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK